CHMP recommends new immunotherapy delivery method
If approved, Roche’s Tecentriq subcutaneous (SC) would be the EU’s first injectable PD-(L)1 cancer immunotherapy.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
